/
Neurology
Epilepsy
52
Pipeline Programs↗
159
Active Trials↗
68
Companies Involved↗
Epilepsy is a moderately active landscape with 52 programs across 68 companies. The most active players are UCB, Supernus Pharmaceuticals, Inc., Immedica Pharma AB. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 18
Phase 27
Phase 36
Approved
No programs
Analysis
Modality Breakdown
93%
Small molecule
43 of 46 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 46 classified programs, each share of the total. Modality classified for 94% of 52 pipeline programs.
Analysis
Trial Status
498
clinical trials
Completed232 · 47%
Recruiting86 · 17%
Unknown status46 · 9%
Not yet recruiting37 · 7%
Terminated36 · 7%
Active, not recruiting21 · 4%
Other40 · 8%
Clinical Trials
Trial Activity
498 trials
Effect of Blue Light on Vagus Nerve Stimulation in Patients With Refractory Epilepsy
Recruiting·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Preclinical·NCT06304389·34 enrolled
Mapping of Human Cognition
Recruiting·TThe University of Texas Health Science Center, Houston·Preclinical·NCT05989893·75 enrolled
Identification of Biomarkers for Vagus Nerve Stimulation in Patients With Refractory Epilepsy
Recruiting·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Preclinical·NCT07909486·20 enrolled
Surgery as a Treatment for Medically Intractable Epilepsy
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT01273129·300 enrolled
Tumor Related Epilepsy
Recruiting·National Institute of Neurological Disorders and Stroke (NINDS)·N/A·NCT02639325·100 enrolled
Page 1 of 34
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)